Literature DB >> 9661036

In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic.

S Tamura1, S Miyazaki, K Tateda, A Ohno, Y Ishii, T Matsumoto, N Furuya, K Yamaguchi.   

Abstract

The in vivo antibacterial activities of a new oral trinem, sanfetrinem cilexetil (a prodrug of sanfetrinem), were evaluated in comparison with those of cefdinir and amoxicillin. Sanfetrinem cilexetil showed potent efficacy against experimental murine septicemia caused by Staphylococcus aureus, Streptococcus pyogenes, and Escherichia coli and against murine respiratory infections caused by Streptococcus pneumoniae. Likewise, in murine models of respiratory infection by penicillin-susceptible and penicillin-resistant S. pneumoniae, sanfetrinem cilexetil was more effective than amoxicillin in reducing the number of bacteria in infected lungs. These results were reflected in its potent in vitro activity and high levels in plasma.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9661036      PMCID： PMC105698     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro activity of the tricyclic beta-lactam GV104326.

Authors:  R Wise; J M Andrews; N Brenwald
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors:  K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.

Authors:  K V Singh; T M Coque; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 4.  Treatment of lower respiratory infections.

Authors:  J T Macfarlane
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

5.  In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria.

Authors:  E Di Modugno; I Erbetti; L Ferrari; G Galassi; S M Hammond; L Xerri
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 6.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

7.  MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

8.  Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice.

Authors:  K Takashima; K Tateda; T Matsumoto; T Ito; Y Iizawa; M Nakao; K Yamaguchi
Journal:  J Med Microbiol       Date:  1996-11       Impact factor: 2.472

9.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191
  9 in total
  5 in total

1.  Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.

Authors:  E Nicolaides; E Galia; C Efthymiopoulos; J B Dressman; C Reppas
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 2.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.

Authors:  S Miyazaki; T Hosoyama; N Furuya; Y Ishii; T Matsumoto; A Ohno; K Tateda; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 4.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 5.  Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Authors:  Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.